SEC Form SC 13G filed by C4 Therapeutics Inc.
$CCCC
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/19/2024 | $8.00 → $12.00 | Equal Weight → Overweight | Wells Fargo |
11/18/2024 | $4.00 | Equal-Weight | Stephens |
1/29/2024 | $6.00 | Underweight → Neutral | JP Morgan |
12/13/2023 | $2.00 → $12.00 | Hold → Buy | Stifel |
2/24/2023 | $12.00 → $10.00 | Underperform → Neutral | Credit Suisse |
2/24/2023 | $15.00 → $5.00 | Neutral → Underweight | JP Morgan |
11/4/2022 | $22.00 → $15.00 | Overweight → Neutral | JP Morgan |
10/11/2022 | $6.00 | Underweight | Morgan Stanley |
8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)